

Concentration-dependent polymorphism of insulin amyloid fibrils

Andrius Sakalauskas¹, Mantas Ziaunys¹, Vytautas Smirnovas^{Corresp. 1}

¹ Department of Biothermodynamics and Drug Design, Vilnius University, Life Sciences Center, Institute of Biotechnology, Vilnius, Lithuania

Corresponding Author: Vytautas Smirnovas
Email address: vytautas@smirnovas.info

Protein aggregation into highly structured fibrils has long been associated with several neurodegenerative disorders, such as Alzheimer's or Parkinson's disease. Polymorphism of amyloid fibrils increases the complexity of disease mechanisms and may be one of the reasons for slow progress in drug research. Here we report protein concentration as another factor leading to polymorphism of insulin amyloid fibrils. Moreover, our data suggests that insulin amyloid conformation can self-replicate only via elongation, while seed-induced nucleation will lead to environment-defined conformation of fibrils. As similar observations were already described for a couple of other amyloid proteins, we suggest it to be a generic mechanism for self-replication of different amyloid fibril conformations.

1 **Concentration-dependent polymorphism of insulin amyloid** 2 **fibrils**

3

4 Andrius Sakalauskas, Mantas Ziaunys, Vytautas Smirnovas

5

6 Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania

7

8 Corresponding Author:

9 Vytautas Smirnovas

10 Sauletekio al. 7, Vilnius, LT-10257, Lithuania

11

12 Email address: vytautas.smirnovas@bti.vu.lt

13

14 **Abstract**

15 Protein aggregation into highly structured fibrils has long been associated with several
16 neurodegenerative disorders, such as Alzheimer's or Parkinson's disease. Polymorphism of
17 amyloid fibrils increases the complexity of disease mechanisms and may be one of the reasons
18 for slow progress in drug research. Here we report protein concentration as another factor
19 leading to polymorphism of insulin amyloid fibrils. Moreover, our data suggests that insulin
20 amyloid conformation can self-replicate only via elongation, while seed-induced nucleation will
21 lead to environment-defined conformation of fibrils. As similar observations were already
22 described for a couple of other amyloid proteins, we suggest it to be a generic mechanism for
23 self-replication of different amyloid fibril conformations.

24 **Introduction**

25 Protein aggregation into amyloid fibrils has been linked to multiple neurodegenerative disorders,
26 including Alzheimer's, Parkinson's and infectious prion diseases (Chiti and Dobson 2017;
27 Knowles, Vendruscolo, and Dobson 2014), which affect tens of millions of people worldwide
28 and is predicted to become even more prominent as the average human lifespan continues to
29 increase (Isik 2010). Matters are further complicated by the fact that very few drugs have
30 reached stage four of clinical trials and no efficient treatment or cure is available (Cummings et
31 al. 2019; Mehta et al. 2017). One of the main reasons for such limited progress in the
32 development of potential cures may be the complexity of fibril formation mechanisms (Meisl et
33 al. 2017), as well as polymorphism of amyloid aggregates (Stein and True 2014).

34 Ability of the same protein to adopt distinct pathogenic conformations was first reported in
35 studies of infectious prions and such conformations were referred to as strains (Safar et al. 1998;
36 Collinge and Clarke 2007). Recently strain-like polymorphism was reported for a number of

37 amyloid proteins both *in vivo* (Lu et al. 2013; Watts et al. 2014; Fändrich et al. 2018; Yamasaki
38 et al. 2019) and *in vitro* (Heise et al. 2005; Paravastu et al. 2008; Debelouchina et al. 2010;
39 Dinkel et al. 2011; Bousset et al. 2013). A number of environmental factors including pH
40 (Sneideris et al. 2015), temperature (Tanaka et al. 2006; Colby et al. 2009), concentration of co-
41 solvents (Dzwolak et al. 2004; Chatani et al. 2012), denaturants (Colby et al. 2009; Cobb et al.
42 2014) or salts (Morel et al. 2010; Bousset et al. 2013), as well as agitation (Petkova et al. 2005;
43 Ostapchenko et al. 2010) can lead to different conformations of amyloid fibrils. Enormous
44 amounts of data must be collected and analyzed in order to understand the complex effects of
45 environment on polymorphism of amyloids.

46 Due to its relatively low cost, wide availability and simple aggregation protocols, insulin became
47 one of the most common proteins used to study amyloid fibril formation. Several years ago, we
48 summarized available data on polymorphism of insulin amyloid fibrils and came with the
49 hypothesis that the number of insulin amyloid conformations may be limited to two and the
50 major factor which determines formation of different strains is a shift of the equilibrium between
51 insulin monomers and dimers (oligomers) (Sneideris et al. 2015). Our current data supports the
52 existence of a third conformation of insulin amyloid fibrils and suggests that polymorphism of
53 insulin amyloid fibrils is more complex.

54 **Materials and Methods**

55 **Insulin sample preparation**

56 Human recombinant insulin powder (Sigma-Aldrich cat. No. 91077C) was dissolved in a 20%
57 acetic acid solution containing 100 mM NaCl (reaction solution) to a final concentration of 2
58 mM (11.6 mg/ml). Insulin concentration was determined by measuring the sample's absorbance
59 at 280 nm $\epsilon=6335 \text{ M}^{-1}\text{cm}^{-1}$, $M = 5808 \text{ Da}$. Samples for unseeded aggregation kinetic
60 measurements were prepared by diluting the 2 mM stock solution using the reaction solution and
61 10 mM ThT stock solution to a range of concentrations from 0.2 mM to 1.0 mM (which
62 contained 100 μM of ThT). For seeded aggregation, insulin fibrils prepared from the 0.2 mM and
63 1.0 mM samples were sonicated for 10 min using Sonopuls 3100 (Bandelin) ultrasonic
64 homogenizer equipped with a MS73 tip (40% power, 30 s sonication/ 30 s rest intervals). The
65 homogenized fibrils were then diluted with the reaction solution and mixed with the 2 mM
66 insulin and 10 mM ThT stock solutions to yield 0.2 mM and 1.0 mM concentration samples
67 containing 100 μM ThT and a range of fibril concentrations (from 5 % to 10^{-6} % of monomer
68 mass).

69 **Aggregation kinetics**

70 Insulin aggregation kinetics were monitored at 60 °C without agitation by measuring ThT
71 fluorescence emission intensity (excitation wavelength - 440 nm, emission - 480 nm) through the
72 bottom of a 96 well non-binding surface plate using Synergy H4 Hybrid Multi-Mode (Biotek)
73 plate reader (readouts were taken every 10 min to minimize plate agitation). For every condition

74 4 independent measurements were performed. Aggregation half-times (t_{50}) were calculated as the
75 time needed to reach 50% of signal intensity.

76

77 **Atomic Force Microscopy (AFM)**

78

79 After kinetic measurements, samples were diluted with the reaction solution to a 50 μM
80 concentration and 20 μL of each was deposited on freshly cleaved mica and incubated for 1 min.
81 Subsequently, samples were rinsed with 1 mL of MilliQ water and dried under gentle airflow.
82 Three-dimensional AFM maps were acquired using a Dimension Icon (Bruker) atomic force
83 microscope operating in tapping mode and equipped with a silicon cantilever Tap300AI-G (40 N
84 m^{-1} , Budget Sensors) with a typical tip radius of curvature of 8 nm. High-resolution (1024 x 1024
85 pixels) images were acquired. The scan rate was 1 Hz. AFM images were flattened and analyzed
86 using SPIP (Image Metrology).

87

88 **Fourier-Transform Infrared (FTIR) Spectroscopy**

89

90 Insulin fibrils were separated from solution by centrifugation at 10 000 g for 30 min and
91 subsequently resuspended in 1 mL of D_2O , the procedure was repeated three times. Then the
92 fibrils were resuspended in 0.2 mL of D_2O and sonicated for 1 min using a MS72 tip (with 20%
93 power and constant sonication). Samples were deposited between two CaF_2 transmission
94 windows separated by 0.05 mm teflon spacers. The FTIR spectra were recorded using Vertex
95 80v (Bruker) IR spectrometer equipped with a mercury cadmium telluride detector, at room
96 temperature under vacuum (~ 2 mBar) conditions. 256 interferograms of 2 cm^{-1} resolution were
97 averaged for each spectrum. Spectrum of D_2O was subtracted from the spectrum of each sample.
98 All spectra were normalized to the same area of amide I/I' band (1700-1595 cm^{-1}). All data
99 processing was performed using GRAMS software.

100

101 **Results**

102

103 **Fibril formation at different concentrations**

104 Aggregating a range of insulin concentrations in 20% acetic acid with 100 mM NaCl at 60 $^\circ\text{C}$
105 without agitation reveals a typical kinetic curve pattern, where an increasing insulin
106 concentration leads to shorter aggregation times (Fig. 1A). However, we observe an uneven ratio
107 distribution between ThT fluorescence emission intensities and final fibril concentrations (Fig.
108 1B). As the concentration of insulin in the sample increases, this ratio shifts ten-fold, indicating
109 either a higher quantum yield or considerably more bound ThT molecules.

110 -FTIR spectra of aggregated samples exhibit maxima in the amide I/I' region at ~ 1628 cm^{-1} with
111 the shoulder at ~ 1641 cm^{-1} , and a small band outside of the amide I/I' region at ~ 1729 cm^{-1} (Fig.
112 1C), which is very similar to previously reported insulin fibrils formed in phosphate buffer at
113 $\text{pH} \leq 2$ [Sneideris2015]. However, minor concentration-dependent differences can be observed

114 (Fig. 1C and D). Spectra of fibrils, formed at lower insulin concentrations have a pronounced
115 shoulder at 1641 cm^{-1} , while a minor band at 1620 cm^{-1} appears in second derivative spectra
116 (Fig. 1D) of samples aggregated at higher protein concentrations. The 1.0 mM and 0.8 mM fibril
117 spectra are nearly identical, while 0.6 mM and 0.4 mM spectra appear to be intermediates
118 between 0.8 mM and 0.2 mM, suggesting the existence of two distinct conformations.

119

120 **Fibril morphology**

121 The morphology of insulin fibrils formed at different concentrations was compared using AFM.
122 We can see far more small and separated aggregates in samples formed at lower insulin
123 concentration (Fig. 2A-E). Analysis of variance (ANOVA) reveals that there is a statistically
124 relevant fibril height difference ($p=0.01$, $n=50$) between the low and high concentration samples
125 (Fig. 2F). Additional AFM images of these conditions are available as supplementary
126 information (Supplementary Fig. S1).

127

128 **Seeded aggregation**

129 In order to determine whether observed different fibril templates can propagate at unfavorable
130 conditions, a set of seeded aggregation reactions were performed (Fig. 3A-D, Supplementary
131 Fig. S2). In all four cases we observe a fibril-concentration-dependent seeding propensity (Fig.
132 3E), however, there is an interesting ThT fluorescence distribution, based on the amount and
133 type of seed added (Fig. 3F). When the 0.2 mM-formed fibril conformation is added to 0.2 mM
134 insulin solutions, there are relatively no major differences in the fluorescence intensity at the end
135 of each reaction. The same can be said in the case when the 1.0 mM-formed conformation is
136 added to 1.0 mM insulin solutions. However, when the 0.2 mM-formed conformation is added to
137 1.0 mM insulin solutions, high seed concentrations yield a low fluorescence intensity, which then
138 rises with decreased amount of seeds, eventually resulting in an intensity comparable to the 1.0
139 mM-formed conformation. The opposite is observed when 1.0 mM-formed seeds are added to
140 0.2 mM insulin solutions, where high initial fibril concentrations yield an intensity comparable to
141 the seed conformation (when accounted for fibril concentration at the end of the reaction) and an
142 intensity similar to fibrils formed at 0.2 mM when the seed concentration becomes minimal.
143 In order to further confirm the self-replication ability of both conformations, fibrils formed
144 during seeded aggregation were examined by FTIR and their spectra were compared to the
145 unseeded aggregation fibril spectra (Fig. 4A-D). The results show that when a large
146 concentration of preformed fibrils is added to either 0.2 mM or 1.0 mM insulin solutions, the
147 seed self-replicates and maintains its initial secondary structure. On the other hand, when a low
148 concentration of seed is added, the resulting FTIR spectra are similar to their respective
149 environment conformations, rather than the seed.

150 **Seeded fibril morphology**

151 When large amounts of sonicated aggregates are used, there is minimal difference in the length
152 and distribution of fibrils (Fig. 5A-D), likely due to the large amount of aggregation centers.
153 When the amount of seed used is low, the fibril length and distribution is similar to unseeded

154 aggregation (Fig. 5E-H). Fibril height distribution reveals a similarity between almost all
155 conditions, except for when 1.0 mM insulin is seeded with low concentrations of either
156 conformation (Fig. 5I), where the height distribution is comparable to unseeded nucleation.
157 Additional AFM images of these conditions are available as supplementary information
158 (Supplementary Fig. S3).

159 **Discussion**

160 The first and most apparent difference between the samples, aggregated at different protein
161 concentrations is their ability to enhance ThT fluorescence. A very similar effect was reported in
162 case of protein-concentration-dependent polymorphism of glucagon amyloid fibrils (Pedersen et
163 al. 2006). A 10-fold increase in ThT binding positions is highly improbable and slightly different
164 fibril size distribution seen in AFM images could not strongly affect the number of binding
165 positions, so a more appropriate explanation could be changes in the fibril's surface, facilitating a
166 different ThT binding mode, as insulin fibrils have been shown to possess more than one way of
167 incorporating ThT molecules (Groenning et al. 2007). Similar differences in ThT fluorescence
168 were observed with different conformations of alpha-synuclein fibrils and attributed to the
169 different binding of ThT molecules (Sidhu et al. 2018), so we can hypothesize that low protein
170 concentration leads to different conformation of insulin amyloid fibrils.

171 Protein-concentration-dependent polymorphism of insulin amyloid fibrils is supported also by
172 different FTIR spectra. In fact, spectral differences are rather minor in comparison to the ones
173 observed between spectra of previously reported insulin conformations (Dzwołak et al. 2004;
174 Sneideris et al. 2015), but the hallmark of each spectrum is conserved in seeding experiments
175 (Fig. 4A and B), which supports the hypothesis of different amyloid conformations. Comparison
176 of FTIR spectra to the previously reported data (Sneideris et al. 2015) suggests that fibril
177 conformation formed at higher insulin concentration is the same as previously reported, while the
178 one formed at lower concentration fall out of the previously proposed scheme (Sneideris et al.
179 2015).

180 Atomic force microscopy data does not add much of information. It seems that average size of
181 spontaneously formed fibrils slightly increases with higher protein concentration (Fig. 2), but this
182 effect does not depend on the type of seeds (Fig. 5).

183 Currently we are aware of two mechanisms of seed-induced aggregation. One is amyloid fibril
184 elongation via attachment and refolding of protein molecules at seed fibril ends, another one is
185 formation of new aggregation nuclei catalyzed by the surface of seeds (often referred as
186 secondary nucleation (Meisl et al. 2016)). Previously we have demonstrated that in case of cross-
187 seeding of different environment-induced conformations of prion protein amyloid fibrils, the
188 conformational template can self-propagate only via elongation mechanism, while surface
189 induced nucleation only speeds up the aggregation process, but the conformation is defined by
190 the environment conditions (Sneideris, Milto, and Smirnovas 2015). Recently similar
191 observations were reported on amyloid beta (Brännström et al. 2018) and alpha synuclein
192 (Peduzzo, Linse, and Buell 2019). Our cross-environment seeding data on insulin follows the

193 same path. With higher amount of seeds the aggregation kinetic curves are exponential which
194 means that the majority of the protein is aggregated via elongation of seeds – in such case the
195 final relative ThT fluorescence intensity and FTIR spectra of seeds and final aggregates are very
196 similar. Lowering the amount of seeds leads to sigmoid kinetic curves which means that the
197 majority of the protein is aggregated via new-formed nuclei and seeds are mainly employed as
198 catalyzers – in such case the final relative ThT fluorescence intensity and FTIR spectra of seeds
199 and final aggregates are different.

200

201 **Conclusions**

202 Generally, in the seeded growth experiment of amyloid fibrils one expects self-replication of
203 seed conformation. Here we showed that such expectations are valid only at certain
204 circumstances – amyloid fibrils self-replicate their conformation only via elongation, else the
205 conformation of aggregates is environment-dependent. As similar conclusions were previously
206 derived in studies of prion protein, amyloid beta, and alpha-synuclein, there may be enough data
207 to consider it as a general way for self-replication of different amyloid fibril conformations.

208

209

210 **References**

- 211 Bousset, Luc, Laura Pieri, Gemma Ruiz-Arlandis, Julia Gath, Poul Henning Jensen, Birgit
212 Habenstein, Karine Madiona, Vincent Olieric, Anja Böckmann, Beat H. Meier, Ronald
213 Melki. 2013. “Structural and Functional Characterization of Two Alpha-Synuclein Strains.”
214 *Nature Communications* 4. <https://doi.org/10.1038/ncomms3575>.
- 215 Brännström, Kristoffer, Tohidul Islam, Anna L. Gharibyan, Irina Iakovleva, Lina Nilsson, Cheng
216 Choo Lee, Linda Sandblad, Annelie Pamrén, and Anders Olofsson. 2018. “The Properties
217 of Amyloid- β Fibrils Are Determined by Their Path of Formation.” *Journal of Molecular*
218 *Biology* 430 (13): 1940–49. <https://doi.org/10.1016/j.jmb.2018.05.001>.
- 219 Chatani, Eri, Hisashi Yagi, Hironobu Naiki, and Yuji Goto. 2012. “Polymorphism of β 2 -
220 Microglobulin Amyloid Fibrils Manifested by Ultrasonication-Enhanced Fibril Formation
221 in Trifluoroethanol.” *Journal of Biological Chemistry* 287 (27): 22827–37.
222 <https://doi.org/10.1074/jbc.M111.333310>.
- 223 Chiti, Fabrizio, and Christopher M. Dobson. 2017. “Protein Misfolding, Amyloid Formation, and
224 Human Disease: A Summary of Progress Over the Last Decade.” *Annual Review of*
225 *Biochemistry* 86 (1): 27–68. <https://doi.org/10.1146/annurev-biochem-061516-045115>.
- 226 Cobb, Nathan J., Marcin I. Apostol, Shugui Chen, Vytautas Smirnovas, and Witold K. Surewicz.
227 2014. “Conformational Stability of Mammalian Prion Protein Amyloid Fibrils Is Dictated
228 by a Packing Polymorphism within the Core Region.” *Journal of Biological Chemistry* 289
229 (5): 2643–50. <https://doi.org/10.1016/j.jmb.2010.05.051>.
- 230 Colby, David W., Kurt Giles, Giuseppe Legname, Holger Wille, Ilia V. Baskakov, Stephen J.
231 DeArmond, and Stanley B. Prusiner. 2009. “Design and Construction of Diverse
232 Mammalian Prion Strains.” *Proceedings of the National Academy of Sciences* 106 (48):
233 20417–22. <https://doi.org/10.1073/pnas.0910350106>.
- 234 Collinge, John, and Anthony R. Clarke. 2007. “A General Model of Prion Strains and Their
235 Pathogenicity.” *Science* 318 (5852): 930–36. <https://doi.org/10.1126/science.1138718>.
- 236 Cummings, Jeffrey, Garam Lee, Aaron Ritter, Marwan Sabbagh, and Kate Zhong. 2019.
237 “Alzheimer’s Disease Drug Development Pipeline: 2019.” *Alzheimer’s & Dementia:*
238 *Translational Research & Clinical Interventions* 5: 272–93.
239 <https://doi.org/10.1016/j.trci.2019.05.008>.
- 240 Debelouchina, Galia T., Geoffrey W. Platt, Marvin J. Bayro, Sheena E. Radford, and Robert G.
241 Griffin. 2010. “Magic Angle Spinning NMR Analysis of β 2 -Microglobulin Amyloid
242 Fibrils in Two Distinct Morphologies.” *Journal of the American Chemical Society* 132 (30):
243 10414–23. <https://doi.org/10.1021/ja102775u>.
- 244 Dinkel, Paul D., Ayisha Siddiqua, Huy Huynh, Monil Shah, and Martin Margittai. 2011.
245 “Variations in Filament Conformation Dictate Seeding Barrier between Three- and Four-
246 Repeat Tau.” *Biochemistry* 50 (20): 4330–36. <https://doi.org/10.1021/bi2004685>.
- 247 Dzwolak, Wojciech, Vytautas Smirnovas, Ralf Jansen, and Roland Winter. 2004. “Insulin Forms

- 248 Amyloid in a Strain-Dependent Manner: An FT-IR Spectroscopic Study.” *Protein Science*
249 13 (7): 1927–32. <https://doi.org/10.1110/ps.03607204>.
- 250 Fändrich, M., S. Nyström, K. P. R. Nilsson, A. Böckmann, H. LeVine, and P. Hammarström.
251 2018. “Amyloid Fibril Polymorphism: A Challenge for Molecular Imaging and Therapy.”
252 *Journal of Internal Medicine* 283 (3): 218–37. <https://doi.org/10.1111/joim.12732>.
- 253 Groenning, Minna, Mathias Norrman, James M. Flink, Marco van de Weert, Jens T. Bukrinsky,
254 Gerd Schluckebier, and Sven Frokjaer. 2007. “Binding Mode of Thioflavin T in Insulin
255 Amyloid Fibrils.” *Journal of Structural Biology* 159 (3): 483–97.
256 <https://doi.org/10.1016/j.jsb.2007.06.004>.
- 257 Heise, Henrike, Wolfgang Hoyer, Stefan Becker, Ovidiu C. Andronesi, Dietmar Riedel, and
258 Marc Baldus. 2005. “Molecular-Level Secondary Structure, Polymorphism, and Dynamics
259 of Full-Length -Synuclein Fibrils Studied by Solid-State NMR.” *Proceedings of the*
260 *National Academy of Sciences* 102 (44): 15871–76.
261 <https://doi.org/10.1073/pnas.0506109102>.
- 262 Isik, Ahmet Turan. 2010. “Late Onset Alzheimer’s Disease in Older People.” *Clinical*
263 *Interventions in Aging* 5 (October): 307–11. <https://doi.org/10.2147/CIA.S11718>.
- 264 Knowles, Tuomas P J, Michele Vendruscolo, and Christopher M. Dobson. 2014. “The Amyloid
265 State and Its Association with Protein Misfolding Diseases.” *Nature Reviews Molecular*
266 *Cell Biology* 15 (6): 384–96. <https://doi.org/10.1038/nrm3810>.
- 267 Lu, Jun-Xia, Wei Qiang, Wai-Ming Yau, Charles D. Schwieters, Stephen C. Meredith, and
268 Robert Tycko. 2013. “Molecular Structure of β -Amyloid Fibrils in Alzheimer’s Disease
269 Brain Tissue.” *Cell* 154 (6): 1257–68. <https://doi.org/10.1016/j.cell.2013.08.035>.
- 270 Mehta, Dev, Robert Jackson, Gaurav Paul, Jiong Shi, and Marwan Sabbagh. 2017. “Why Do
271 Trials for Alzheimer’s Disease Drugs Keep Failing? A Discontinued Drug Perspective for
272 2010-2015.” *Expert Opinion on Investigational Drugs* 26 (6): 735–39.
273 <https://doi.org/10.1080/13543784.2017.1323868>.
- 274 Meisl, Georg, Julius B Kirkegaard, Paolo Arosio, Thomas C T Michaels, Michele Vendruscolo,
275 Christopher M Dobson, Sara Linse, and Tuomas P J Knowles. 2016. “Molecular
276 Mechanisms of Protein Aggregation from Global Fitting of Kinetic Models.” *Nature*
277 *Protocols* 11 (2): 252–72. <https://doi.org/10.1038/nprot.2016.010>.
- 278 Meisl, Georg, Luke Rajah, Samuel A. I. Cohen, Manuela Pfammatter, Anđela Šarić, Erik
279 Hellstrand, Alexander K. Buell, Adriano Aguzzi, Sara Linse, Michele Vendruscolo,
280 Christopher M. Dobson, Tuomas P. J. Knowles. 2017. “Scaling Behaviour and Rate-
281 Determining Steps in Filamentous Self-Assembly.” *Chemical Science* 8 (10): 7087–97.
282 <https://doi.org/10.1039/C7SC01965C>.
- 283 Morel, Bertrand, Lorena Varela, Ana I. Azuaga, and Francisco Conejero-Lara. 2010.
284 “Environmental Conditions Affect the Kinetics of Nucleation of Amyloid Fibrils and
285 Determine Their Morphology.” *Biophysical Journal* 99 (11): 3801–10.
286 <https://doi.org/10.1016/j.bpj.2010.10.039>.
- 287 Ostapchenko, Valeriy G., Michael R. Sawaya, Natallia Makarava, Regina Savtchenko, K. Peter

- 288 R. Nilsson, David Eisenberg, and Ilia V. Baskakov. 2010. “Two Amyloid States of the
289 Prion Protein Display Significantly Different Folding Patterns.” *Journal of Molecular*
290 *Biology* 400 (4): 908–21. <https://doi.org/10.1016/j.jmb.2010.05.051>.
- 291 Paravastu, Anant K., Richard D. Leapman, W.-M. Yau, and Robert Tycko. 2008. “Molecular
292 Structural Basis for Polymorphism in Alzheimer’s β -Amyloid Fibrils.” *Proceedings of the*
293 *National Academy of Sciences* 105 (47): 18349–54.
294 <https://doi.org/10.1073/pnas.0806270105>.
- 295 Pedersen, Jesper Søndergaard, Dantcho Dikov, James L. Flink, Hans Aage Hjuler, Gunna
296 Christiansen, and Daniel Erik Otzen. 2006. “The Changing Face of Glucagon Fibrillation:
297 Structural Polymorphism and Conformational Imprinting.” *Journal of Molecular Biology*
298 355 (3): 501–23. <https://doi.org/10.1016/j.jmb.2005.09.100>.
- 299 Peduzzo, Alessia, Sara Linse, and Alexander Buell. 2019. “The Properties of α -Synuclein
300 Secondary Nuclei Are Dominated by the Solution Conditions Rather than the Seed Fibril
301 Strain.” *ChemRxiv*. doi:10.26434/chemrxiv.9757778.v1.
- 302 Petkova, Aneta T., Richard D Leapman, Zhihong Guo, Wai-Ming Yau, Mark P Mattson, and
303 Robert Tycko. 2005. “Self-Propagating, Molecular-Level Polymorphism in Alzheimer’s
304 Beta-Amyloid Fibrils.” *Science* 307 (5707): 262–65.
305 <https://doi.org/10.1126/science.1105850>.
- 306 Safar, Jiri, Holger Wille, Vincenza Itri, Darlene Groth, Hana Serban, Marilyn Torchia, Fred E.
307 Cohen, and Stanley B. Prusiner. 1998. “Eight Prion Strains Have PrPSc Molecules with
308 Different Conformations.” *Nature Medicine* 4 (10): 1157–65. <https://doi.org/10.1038/2654>.
- 309 Sidhu, Arshdeep, Jonathan Vaneyck, Christian Blum, Ine Segers-Nolten, and Vinod
310 Subramaniam. 2018. “Polymorph-Specific Distribution of Binding Sites Determines
311 Thioflavin-T Fluorescence Intensity in α -Synuclein Fibrils.” *Amyloid* 25 (3): 189–96.
312 <https://doi.org/10.1080/13506129.2018.1517736>.
- 313 Sneideris, Tomas, Domantas Darguzis, Akvile Botyriute, Martynas Grigaliunas, Roland Winter,
314 and Vytautas Smirnovas. 2015. “pH-Driven Polymorphism of Insulin Amyloid-Like
315 Fibrils.” Edited by Byron Caughey. *PLoS One* 10 (8): e0136602.
316 <https://doi.org/10.1371/journal.pone.0136602>.
- 317 Sneideris, Tomas, Katažyna Milto, and Vytautas Smirnovas. 2015. “Polymorphism of Amyloid-
318 like Fibrils Can Be Defined by the Concentration of Seeds.” *PeerJ* 3 (August): e1207.
319 <https://doi.org/10.7717/peerj.1207>.
- 320 Stein, Kevin C., and Heather L. True. 2014. “Prion Strains and Amyloid Polymorphism
321 Influence Phenotypic Variation.” *PLoS Pathogens* 10 (9): e1004328.
322 <https://doi.org/10.1371/journal.ppat.1004328>.
- 323 Tanaka, Motomasa, Sean R. Collins, Brandon H. Toyama, and Jonathan S. Weissman. 2006.
324 “The Physical Basis of How Prion Conformations Determine Strain Phenotypes.” *Nature*
325 442 (7102): 585–89. <https://doi.org/10.1038/nature04922>.
- 326 Watts, Joel C., Carlo Condello, J. Stohr, Abby Oehler, Joanne Lee, Stephen J. DeArmond, Lars
327 Lannfelt, Martin Ingelsson, Kurt Giles, and Stanley B. Prusiner. 2014. “Serial Propagation

328 of Distinct Strains of A Prions from Alzheimer’s Disease Patients.” *Proceedings of the*
329 *National Academy of Sciences* 111 (28): 10323–28.
330 <https://doi.org/10.1073/pnas.1408900111>.

331 Yamasaki, Tritia R., Brandon B. Holmes, Jennifer L. Furman, Dhruva D. Dhavale, Bryant W.
332 Su, Eun-Suk Song, Nigel J. Cairns, Paul T. Kotzbauer, and Marc I. Diamond. 2019.
333 “Parkinson’s Disease and Multiple System Atrophy Have Distinct α -Synuclein Seed
334 Characteristics.” *Journal of Biological Chemistry* 294 (3): 1045–58.
335 [doi:10.1074/jbc.RA118.004471](https://doi.org/10.1074/jbc.RA118.004471).

336

Figure 1

Concentration-dependent differences of insulin aggregation.

Aggregation kinetics of unseeded insulin in 20% acetic acid with 100 mM NaCl at 60 °C without agitation followed by ThT fluorescence (A), insert shows aggregation kinetics of 0.2 mM insulin. Each kinetic data point is the average of 4 repeats. ThT fluorescence intensity and fibril concentration ratios (B). FTIR absorption (C) and second derivative (D) spectra of insulin fibrils.




Figure 2

AFM analysis of insulin fibrils.

Insulin fibrils formed at 0.2 mM (A), 0.4 mM (B), 0.6 mM (C), 0.8 mM (D) and 1.0 mM (E) concentrations. Insulin fibril height distribution with box plots indicating the interquartile range and errors bars are for 1 standard deviation (F). Sample size for each ANOVA test was 50.




Figure 3

Seeded aggregation of insulin with a range of preformed fibrils.

Aggregation kinetics of insulin where the 0.2 mM-formed conformation is added to 0.2 mM insulin solutions (A), 0.2 mM-formed conformation to 1.0 mM (B), 1.0 mM-formed conformation to 0.2 mM (C) and 1.0 mM-formed conformation to 1.0 mM (D). Aggregation half-time (t_{50}) dependence on concentration and type of seed added (E). ThT fluorescence intensity and fibril concentration ratio dependence on added seed concentration (F). Each data point is the average of 4 repeats.




Figure 4

FTIR analysis of seeded aggregates.

Absorption and second derivate spectra of insulin fibrils when 5% (A and B respectively) and 0.0001% (C and D respectively) preformed fibrils are added.




Figure 5

AFM analysis of seeded insulin fibrils.

Insulin fibrils resulting from seeding 0.2 mM insulin with 0.2 mM-formed conformation (A, E), 0.2 mM with 1.0 mM-formed (B, F), 1.0 mM with 0.2 mM-formed (C, G), 1.0 mM with 1.0 mM-formed (D, H) using 5% or 10^{-4} % of preformed fibrils respectively. Insulin fibril height distribution with box plots indicating the interquartile range and errors bars are for 1 standard deviation. Sample size for each ANOVA test was 50.

